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Abstract 
This Podcast features an interview with Cristina Murga and Rocio Vila-Bedmar, 
authors of a Research Article that appears in the 21 July 2015 issue of Science 
Signaling, about how deleting the kinase GRK2 can counteract some of the 
metabolic effects of a bad diet. Obesity affects many of the body's normal 
functions, most notably metabolism. Obesity is associated with insulin 
resistance and reduced glucose tolerance, which can lead to type 2 diabetes. It 
also promotes hepatic steatosis, the accumulation of fat in the liver. Vila-
Bedmar et al. show that deleting GRK2 can prevent further weight gain and 
hepatic steatosis and improve glucose sensitivity in obese mice. 
Deleting GRK2 improved these metabolic consequences of high-fat diet–
induced obesity even if the kinase was deleted after the mice had already 
become obese and resistant to insulin. 
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Transcript 
Host – Annalisa VanHookWelcome to the Science Signaling Podcast July 21st, 
2015. I’m Annalisa VanHook, and today I'm speaking with Rocio Vila-Bedmar 
and Cristina Murga about how deleting a particular kinase can counteract some 
of the metabolic effects of a bad diet (1). 
Obesity affects many of the body's normal functions, most notably metabolism. 
Obesity is associated with insulin resistance and reduced glucose tolerance, 
which can lead to type 2 diabetes. It also promotes the accumulation of fat in 
the liver, a condition referred to as hepatic steatosis. A new study from Rocio 
Vila-Bedmar, Cristina Murga, and their colleagues shows that deleting the 
kinase GRK2 can prevent further weight gain and hepatic steatosis and improve 
glucose sensitivity in obese mice. Deleting GRK2 improved these metabolic 
consequences of obesity even if the kinase was deleted after the mice had 
become obese and resistant to insulin. Murga and Vila-Bedmar spoke to me 
from Center for Molecular Biology in Madrid. 
Interviewer – Annalisa VanHookDr. Murga and Dr. Vila-Bedmar, welcome to 
the Science Signaling Podcast. 
Interviewee – Cristina MurgaHello. 
Interviewee – Rocio Vila-BedmarHello. 
Interviewer – Annalisa VanHookRocio, we all know that a high-fat diet and 
obesity have serious metabolic consequences. What are some of the ways in 
which a high-fat diet and obesity disrupt normal metabolism? 
Interviewee – Rocio Vila-BedmarThe effects of a high-fat diet–associated 
obesity and metabolism are indeed numerous and complex. Actually, white 
adipose tissue was classically considered a mere storage depot for energy 
excess, but nowadays it is recognized as an important endocrine organ. In fact, 
adipocytes are able to modulate global energy homeostasis through the 
secretion of several factors known as adipokines. This endocrine function partly 
explains why expansion of adipose tissue may impact whole body metabolism. 
Moreover, when the storage capacity of adipose tissue is surpassed, it results in 
lipid accumulation in tissues other than adipose, what is known as ectopic fat 
deposition. This leads to activation of inflammatory responses, thyroid 
dysfunction, and also impaired insulin sensitivity. And all this situation is known 
as lipotoxicity. Specifically, excessive visceral fat accumulation called central or 
abdominal obesity is considered causally related to metabolic complications 
since the enlarged intra-abdominal adipocytes display an increased fatty acid 
release or increased lipolysis that is resistant to the antilipolytic effect of insulin. 
This increased lipolysis of visceral fat sends fatty acids into the portal 
circulation, leading to impaired insulin sensitivity and to increased glucose 
production in the liver. In addition, this increased flux of free fatty acids 
contributes to increased triglyceride synthesis and hepatic steatosis. 
On the other hand, during obesity, hypertrophic adipocytes shift the immune 
balance towards the production of proinflammatory molecules that lead to the 
polarization of the immune cells such as macrophages from an anti- to a 
proinflammatory state. This conducts to a cell fate cycle of inflammation 
promoting further macrophage recruitment, and all this proinflammatory state 
alters the secretion pattern of adipokines, fostering whole body insulin 
resistance. Moreover, pancreatic β cells try to compensate [for] this systemic 
insulin resistance [by] increasing insulin production, and this hyperinsulinemic 
situation, in turn, further stimulates novel lipogenesis in the liver, contributing to 
the development of hepatic steatosis and complex metabolic dysregulation. 
Thus, expanded visceral adipose tissue would lead not only to altered fatty 
acids and triglyceride metabolism, but also to a global proinflammatory profile 
contributing to the dyslipidemia, insulin resistance, and altered glucose 
homeostasis that underlie metabolic alterations in obese patients. 
Interviewer – Annalisa VanHookCristina, what is GRK2, and why did you focus 
on its role in metabolic dysregulation? 
Interviewee – Cristina MurgaGRK2 is a protein that is capable of incorporating 
phosphate groups into other proteins. This is why it is called a kinase, and this 
ability allows GRK2 to control and to regulate the actions of other important 
proteins in the cell, such as cytosolic effectors and, more importantly, 
membrane receptors. So, it was previously known that GRK2 could help stop 
the intracellular signals that emanated from G protein–coupled receptors. 
However, it was only recently—with our work and that of others—that we could 
establish that GRK2 can also impair and stop signal transduction triggered by 
the insulin receptor. So this is a very important issue since insulin is a key 
metabolic hormone. And this is the main reason why we set out to study 
whether GRK2 could modify metabolic homeostasis during a whole body 
response to insulin. We also analyzed how GRK2 can control insulin actions at 
the cellular level and also in different tissues important for maintaining body 
weight and a normal metabolic regulation. 
Interviewer – Annalisa VanHookRocio, in this study, you deleted the gene that 
encodes GRK2 in mice that had already become obese and had already 
developed insulin resistance as a result of eating a high-fat diet. How does 
deleting GRK2 affect these mice? 
Interviewee – Rocio Vila-BedmarFirst, the global deletion of GRK2 during a 
high-fat diet impaired body weight again that is classically associated to high-fat 
feeding and normalized plasma fasting glucose and insulin levels, which are 
known to be increased in a prediabetic state. Moreover, these mice showed 
improved glucose tolerance and a more potent activation of insulin signaling 
and displayed reduced visceral mass and smaller adipocyte size and were 
resistant to the development of hepatic steatosis and hepatic inflammation. We 
showed that there seemed to be four processes involved in these beneficial 
effects of GRK2 deletion: first, improved insulin signaling in peripheral target 
tissues; second, enhanced lipolysis in white adipose tissue and also in brown 
adipose tissue; third, increased expression of fatty acid oxidation and 
thermogenic markers in brown adipose tissue; and finally, reduced steatosis 
and inflammation in the liver. Such pleiotropic effects of GRK2 are due to both 
its unique ability to directly modulate the insulin receptor and also to modulate 
key G protein–coupled receptors related to the control of adiposity in metabolic 
rates such as β adrenergic receptors. 
In part, some of these effects, such as the reduced adipose fat mass or the 
increased lipolysis found in white adipose tissue, seemed to be related to an 
enhanced response to adrenergic input. However, the improvement in glucose 
tolerance prevailed, even under experimental conditions of adrenergic 
blockade, thus demonstrating that GRK2 loss can influence insulin sensitization 
independently of its effects on the control of adrenergic signaling. Overall, our 
data suggest that, either by directly inhibiting the insulin receptor cascade or 
through the regulation of adrenergic receptors, GRK2 can modulate body 
weight gain, adiposity, metabolic rates, and downstream targets of the insulin 
pathway. Under pathological conditions, concomitant increases in GRK2 
abundance in several tissues would favor the development of an insulin-
resistant phenotype. In contrast, decreases in GRK2 abundance could 
orchestrate a multiorgan response that would reverse systemic and tissue-
specific factors of such insulin resistance and obese phenotype. 
Interviewer – Annalisa VanHookCristina, you knocked out the GRK2 gene in 
your mouse model. Obviously, knocking out a gene is not feasible or advisable 
in human patients. Could there be other ways to inhibit GRK2 function in obese 
patients to prevent metabolic disease? 
Interviewee – Cristina MurgaInhibiting GRK2 could have beneficial effect not 
only for maintaining leanness and for reverting insulin resistance and hepatic 
steatosis as we showed in this manuscript, but it also would be beneficial in the 
treatment of cardiac dysfunction, as was demonstrated by the groups of Bob 
Lefkowitz and Wally Koch and other colleagues (2). So, many laboratories have 
tried along the past decade or so to find an effective and selective inhibitor for 
GRK2. First, we used peptide inhibitors, and they could bind and maybe impair 
GRK2 actions, but they were not very effective. And later, we have tried to 
identify small molecule inhibitors for this kinase without much success. 
However, it was only this year that the group of Dr. Tesmer has finally described 
that paroxetine—a well-established inhibitor of serotonin reuptake—can also 
bind and directly inhibit GRK2 (3). We have not been able to use paroxetine in 
our studies since, apart from inhibiting directly GRK2, it can, of course, affect 
central nervous system components that are key to metabolic regulation. So, 
the use of paroxetine would have obscured our results and our conclusions. 
This is why we had to use genetic ablation of GRK2 as a proof of concept that 
inhibiting this kinase can, indeed, control weight gain and revert insulin 
resistance and also hepatic steatosis in a preclinical model, but this was done in 
the hope [that] more selective inhibitors of GRK2 are developed and available in 
the near future. 
Interviewer – Annalisa VanHookDr. Murga, Dr. Vila-Bedmar, thanks for 
speaking with me. 
Interviewee – Cristina MurgaWell thank you, it was our pleasure. 
Interviewee – Rocio Vila-BedmarThanks to you. Goodbye. 
Host – Annalisa VanHookThat was Cristina Murga and Rocio Vila-Bedmar, 
discussing a paper published in the July 21st issue of issue Science 
Signaling by Vila-Bedmar and colleagues (1). You can read that article online 
at stke.sciencemag.org. 
music 
The Science Signaling Podcast is a production of Science Signaling and the 
American Association for the Advancement of Science—Advancing Science, 
Serving Society. If you have any comments or questions, you can write to us 
atsciencesignalingeditors@aaas.org. I'm Annalisa VanHook, and on behalf 
ofScience Signaling and AAAS, thanks for listening. 
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